Campbell & CO Investment Adviser LLC Sells 19,797 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Campbell & CO Investment Adviser LLC cut its holdings in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 73.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,219 shares of the medical research company’s stock after selling 19,797 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Exact Sciences were worth $534,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Norges Bank acquired a new position in Exact Sciences during the 4th quarter valued at approximately $120,308,000. Jennison Associates LLC grew its position in shares of Exact Sciences by 94.0% during the 4th quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock valued at $100,681,000 after acquiring an additional 659,235 shares during the period. Artisan Partners Limited Partnership increased its stake in shares of Exact Sciences by 12.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock valued at $330,711,000 after purchasing an additional 508,764 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in Exact Sciences by 328.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 540,191 shares of the medical research company’s stock worth $36,852,000 after purchasing an additional 414,059 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Exact Sciences by 47.0% during the fourth quarter. Victory Capital Management Inc. now owns 750,228 shares of the medical research company’s stock worth $55,502,000 after purchasing an additional 239,840 shares in the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on EXAS shares. Jefferies Financial Group assumed coverage on shares of Exact Sciences in a research note on Monday, June 3rd. They issued a “buy” rating and a $75.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Canaccord Genuity Group reduced their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Citigroup lowered their target price on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Finally, TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.07.

Read Our Latest Stock Report on EXAS

Insider Buying and Selling at Exact Sciences

In other news, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the sale, the executive vice president now directly owns 71,787 shares of the company’s stock, valued at approximately $5,025,090. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of Exact Sciences stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the transaction, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at approximately $69,544,888.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sarah Condella sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now directly owns 71,787 shares in the company, valued at approximately $5,025,090. The disclosure for this sale can be found here. Insiders have sold 5,498 shares of company stock valued at $370,105 over the last 90 days. 1.36% of the stock is owned by insiders.

Exact Sciences Trading Down 3.9 %

EXAS opened at $42.93 on Friday. The stock has a market capitalization of $7.92 billion, a PE ratio of -32.52 and a beta of 1.26. Exact Sciences Co. has a one year low of $42.72 and a one year high of $100.77. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.45 and a current ratio of 1.64. The business’s 50 day moving average price is $58.36 and its 200 day moving average price is $62.60.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). The company had revenue of $637.52 million for the quarter, compared to the consensus estimate of $624.95 million. Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. As a group, equities research analysts expect that Exact Sciences Co. will post -1.15 EPS for the current year.

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Further Reading

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.